Overall rank by patents
#24,311
of 50,000 tracked assignees
USPTO PatentsView assignee record - 11 granted patents across 1 technology areas, recorded in grant years 2017–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: H04L (TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION).
The verdict
According to USPTO PatentsView, Exinda ranks #24,311 of 50,000 tracked US assignees by granted-patent volume, with 11 patents across 1 technology areas.
USPTO PatentsView assignee plate
Corpus R24311 · US Corporation #24,311 · 11 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-FLAT · BOOK-FULL
Nearest grant-volume peer: Eutropics Pharmaceuticals, Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Exinda Networks PTY · this assignee
27 score
3D Lighting Innovati… · lowest
7 score
What this shows Exinda's Innovation Score is 27.1/100 (top 78% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Exinda Networks PTY, Ltd. is a focused PatentsView assignee: 1 CPC subclasses with 100% of grants classified under H04L (TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION). Peak complete grant year is 2019 (4 grants) versus a trough of 1 in 2017. By volume, Exinda sits between Eutropics Pharmaceuticals, Inc. and Family Inada Co., Ltd..
Exinda Networks PTY, Ltd. shows 2 grants in 2022–2024 against only 7 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Eutropics Pharmaceuticals, Inc.
11 patents
EverPro Technologies Company Limited
11 patents
Everbridge, Inc.
11 patents
Evolv Technologies, Inc.
11 patents
ExlService Holdings, Inc.
11 patents
Ezaki Glico Co. Ltd.
11 patents
F-star Therapeutics Limited
11 patents
FAMILY INADA CO., LTD.
11 patents
Exinda Networks PTY, Ltd.
11 patents
What this shows Exinda holds 11 patents at rank #24,306, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #24,306 in granted patent volume.
Other assignees with the most granted patents in Exinda's primary technology class.
Exinda's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
27 Top 78% higher than 22% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2017 | 1 | 9.1% |
| 2019 | 4 | 36.4% |
| 2020 | 3 | 27.3% |
| 2022 | 1 | 9.1% |
| 2023 | 1 | 9.1% |
| 2025partial year | 1 | 9.1% |
Top 1 of 1 technology areas
Overall rank by patents
#24,311
of 50,000 tracked assignees
27.1 out of 100
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.